Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Saved in:
Bibliographic Details
Title: Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Authors: Michlmayr, A.1, Bachleitner-Hofmann, T.1, Baumann, S.1, Marchetti-Deschmann, M.2, Rech-Weichselbraun, I.3, Burghuber, C.1, Pluschnig, U.4, Bartsch, R.4, Graf, A.5, Greil, R.6, Allmaier, G.2, Steger, G.4, Gnant, M.1, Bergmann, M.1 rudolf.oehler@meduniwien.ac.at, Oehler, R.1 rudolf.oehler@meduniwien.ac.at
Source: British Journal of Cancer. 10/12/2010, Vol. 103 Issue 8, p1201-1208. 8p. 1 Black and White Photograph, 4 Charts.
Database: Academic Search Ultimate
Description
ISSN:00070920
DOI:10.1038/sj.bjc.6605909